See today's BioWorld
To read the full story, subscribe or sign in.

Phathom down on FDA delay for vonoprazan

Jan. 4, 2023
By Karen Carey and Lee Landenberger
Phathom Pharmaceuticals Inc.’s shares sank 31% on news that the U.S. FDA will not take action on the company’s NDA for oral small-molecule potassium-competitive acid blocker vonoprazan by the Jan. 11 PDUFA date.
BioWorld Regulatory Gastrointestinal FDA